When Weight Loss Outruns Nutrition: A Metabolic-Reserve Hypothesis for Incretin-Associated Decompensation

Potent incretin-based weight-loss therapies can produce substantial reductions in body mass, but treatment success is commonly described by total pounds or percentage of starting weight lost rather than by the tempo of the underlying nutritional transition. This Perspective proposes that weight-loss velocity and nutritional-restriction velocity may carry clinically relevant information independently of cumulative weight loss. The model distinguishes body-weight change from nutritional supply and defines metabolic reserve as the functional margin by which replenishment and compensatory capacity remain sufficient relative to depletion and demand. When nutritional depletion outpaces replenishment and compensation, reserve may decline toward a functional threshold at which small additional losses produce disproportionately large physiological consequences. The hypothesis predicts nonlinear risk concentrated in a susceptible high-velocity tail rather than uniform harm across treated populations. Incretin therapies may therefore remain beneficial for most patients while a smaller subgroup experiences psychiatric, neurologic, autonomic, neuropathic, cardiovascular, or other systemic deterioration. Thiamine is proposed as a separately testable candidate rate-limiting constraint, not as a required explanation for every adverse event; failure of the thiamine-specific branch would not by itself falsify the broader nutritional-velocity model. Competing explanations include direct drug effects independent of nutritional change, baseline disease burden, illness-related weight loss, medication exposure, and other confounding influences. The model is falsifiable: it would be weakened if weight-loss velocity adds no predictive information beyond cumulative loss, if nutritional compromise does not precede or track the proposed phenotype, or if alternative mechanisms better explain the observed pattern. The paper does not propose that incretin-based therapies are generally harmful, but that the speed and nutritional context of weight loss warrant direct study.